Safety And Efficacy Of Rifabutin In Patients For Non-HIV Patients

Pfizer

Status: Completed

Conditions: Tuberculosis; Non-tuberculous Mycobacterial Diseases (Including MAC Disease)

Treatments: Drug: rifabutin

Study type: Observational

Funder types: Industry

Identifiers

NCT00810407

A0061006

Details and patient eligibility

About

The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.

Full description

All the patients whom an investigator prescribes the first Mycobutin® should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.

Enrollment: 628 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients need to be administered Mycobutin® in order to be enrolled in the surveillance.

Exclusion criteria

• Patients not administered Mycobutin®.

Trial design

628 participants in 1 patient group

rifabutin

Description:

Patients administered Rifabutin.

Treatment:

Drug: rifabutin